Oculis To Submit IND For Privosegtor In Acute MS Relapses In Q4 2026, Backed By Positive FDA Pre-IND Guidance And Prior Optic Neuritis Data
The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need The FDA confirmed that
A company got the green light from the FDA to start testing a new medicine for MS flare-ups next year. This is a good sign that the FDA thinks the medicine might work, which means the company's plan has a real chance.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.